CLINICAL-EVALUATION OF A PAF-ANTAGONIST IN PSORIASIS-VULGARIS

Platelet aggregation activating factor (PAF) is proinflammatory mediat or which may be involved in the pathogenesis of psoriasis, The aim of the present investigation was to evaluate the efficacy of Ro24-0238, a highly potent inhibitor of PAF, in the treatment of psoriasis, In a d ouble-blind placebo-controlled within-patient comparative study, 52 pa tients with plaque-type psoriasis were treated with a 10% Ro 24-0238 s olution and vehicle alone, No statistically significant improvement in the Ro 24-0238-treated plaques compared with the vehicle-treated site s could be demonstrated, Therefore, the present study does not provide evidence for a potential role of PAF in the maintenance of well-estab lished plaques of psoriasis.